Federal Officials Trade Stock in Companies Their Agencies Oversee as GM Looks to Parlay Battery Work Into New Energy Business

In today's news, we see federal officials trading stock in companies their agencies oversee, GM looking to expand its battery work into a new energy business, XPO Logistics appointing a CFO, Merck's patent cliff looking less frightening, Cameco and Brookfield Renewable Partners buying Westinghouse Electric Co., how status drives cultural change, the Bank of England further expanding its bond-market rescue, Peloton Co-Founder John Foley facing repeated margin calls from Goldman Sachs as stock slumped, there's a new menace stalking suburbia called the McBasement, and AstraZeneca looking to cancer and RSV drugs for growth as Covid-vaccine demand wanes.

• Federal Officials Trade Stock in Companies Their Agencies Oversee: The stock trading by federal officials of companies they oversee raises potential conflict of interest concerns.
• GM Looks to Parlay Battery Work Into New Energy Business: GM is looking to transition its battery work into a new energy business.
• XPO Logistics Appoints CFO, Assembles Board: XPO logistics has appointed a new CFO and assembled a board.
• Merck’s Patent Cliff Doesn’t Look So Frightening Anymore: Merck's patent cliff doesn't look so frightening anymore.
• Cameco, Brookfield Renewable Partners to Buy Westinghouse Electric Co. for $7.88 Billion: Cameco and Brookfield Renewable Partners are buying Westinghouse Electric Co. for $7.88 billion.
• How Status Drives Cultural Change: How social status can drive cultural change.
• Bank of England Further Expands Bond-Market Rescue: The Bank of England is expanding its bond-market rescue program.
• Peloton Co-Founder John Foley Faced Repeated Margin Calls From Goldman Sachs as Stock Slumped: Peloton co-founder John Foley faced repeated margin calls from Goldman Sachs as the stock slumped.
• There's New Menace Stalking Suburbia. Meet the McBasement...: The McBasement is a new menace stalking suburbia.
• AstraZeneca Looks to Cancer, RSV Drugs for Growth as Covid-Vaccine Demand Wanes: AstraZeneca is looking to cancer and RSV drugs for growth as Covid-vaccine demand wanes.